Arcturus Therapeutics Ltd Up 26.34% To $24.51 After Earnings Beat

Wednesday, November 15, 2023 - Arcturus Therapeutics Ltd (ARCT) reported upside earnings and revenues today.

The consensus among analysts for Arcturus Therapeutics Ltd was for an earnings per share (EPS) loss of $1.69 per share. The firm was able to surpass those projections, reporting an EPS loss of $0.61 per share, a positive surprise of $1.08 (64%). Profits rose 54% year-over-year after reporting an EPS loss of $1.33 per share in its year-ago quarter. The positive growth rate signals that the Healthcare company is performing well amid recent economic conditions.

Revenues were upbeat at $45.1 million. That is an increase of 237.65% in revenues from the year-ago report and is 184.62% higher than consensus estimates set at $15.9 million.

The stock is up 26.34% to $24.51 after the report.

Despite revenues increasing, earnings decreased, signaling a decline in profit margins.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 72. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.